Clinical review report: Ixekizumab (Taltz) (Eli Lilly Canada Inc.) indication : for the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to, or are intolerant to conventional therapy

The objective of this review is to perform a systematic review of the beneficial and harmful effects of Ixekizumab (solution for subcutaneous injection, 80 mg/1.0 mL) for the treatment of adult patients with active Ankylosing spondylitis who have responded inadequately to, or are intolerant to conve...

Full description

Bibliographic Details

Corporate Author:	Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2020, May 2020
Edition:	Version: Final (with redactions)
Series:	CADTH common drug review
Subjects:	Adult Canada Injections, Subcutaneous Antibodies, Monoclonal, Humanized / Adverse Effects Treatment Outcome Spondylitis, Ankylosing / Drug Therapy Antibodies, Monoclonal, Humanized / Therapeutic Use
Online Access:	http://www.ncbi.nlm.nih.gov/books/NBK565108
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa